Does this transaction increase Guardant Health's debt?

Not on a principal basis. Guardant retires about $659.3 million of 2027 Notes and issues $600 million of 2031 Notes, a net reduction of about $59.3 million. However, the new notes carry a 1.25% coupon while the retired 2027 Notes were 0%, so annual cash interest expense rises by roughly $7.5 million on the $600 million principal.

How much dilution could shareholders face from the new notes?

At the initial conversion rate of 16.0716 shares per $1,000 principal, the $600 million of new notes convert into about 9.6 million shares. The filing states a maximum of about 13.0 million shares at the maximum conversion rate of 21.6966 per $1,000, subject to anti-dilution adjustments. Guardant can settle conversions in cash, shares, or a combination, which gives it flexibility to limit share issuance.

Why is Guardant repurchasing its own stock alongside the exchange?

The filing says the company intends to repurchase about $45 million of common stock from certain participants in the transaction, and its exchange agent is expected to buy about $35 million more, both at the February 6, 2025 last reported sale price. These repurchases are tied to the exchange and likely reflect holders of the 2027 Notes hedging or unwinding positions. The filing does not explicitly explain the purpose beyond this linkage, and the repurchases partially offset the dilution from the new notes.

When can holders convert the new notes, and when can Guardant force conversion or redeem them?

Before November 15, 2030, holders can convert only upon specified events. From November 15, 2030 until the second trading day before maturity, they can convert at any time. Guardant cannot redeem the notes before February 21, 2028. After that date, it can redeem them at par plus accrued interest only if the stock exceeds 130% of the conversion price (about $80.89) on at least 20 of 30 consecutive trading days. Calling a note also triggers a make-whole adjustment that increases the conversion rate for holders who convert after the call.

What are the main default and acceleration risks for the new notes?

Events of default include payment defaults, failure to send required notices, certain merger or asset-sale covenant breaches, other covenant defaults not cured within 60 days, cross-default on indebtedness of at least $100 million by the company or significant subsidiaries, and bankruptcy events. Bankruptcy of the parent causes automatic acceleration. For other defaults, the trustee or holders of at least 25% of principal can accelerate. For certain reporting failures, the company can elect special interest of up to 0.50% for up to 180 days as the sole remedy.

GH 8-K: Material Agreements & Securities & Listing

01—Abstract

Summary

Summary of the 8-K filed February 7, 2025. Cited figures are marked; the original filing is the authoritative source.

On February 6, 2025, Guardant Health entered into privately negotiated exchange agreements with certain holders of its 0%^a Convertible Senior Notes due 2027.

The company will issue $600 million^b of new 1.25% Convertible Senior Notes due 2031 in exchange for retiring about $659.3 million of the 2027 Notes, which leaves roughly $490.7 million of the 2027 Notes outstanding on unchanged terms. The transaction is expected to close on or about February 14, 2025. Alongside the exchange, Guardant plans to repurchase about $80 million of its common stock in total: about $45 million from the company directly and about $35 million through the exchange agent, both at the February 6, 2025 last reported sale price.

The company is effectively extending its debt maturity from 2027 to 2031 and cutting the principal outstanding by about $59 million^c, while adding a new coupon of 1.25%. The main investor takeaways are the lower leverage and the cost trade-off. The company's cash interest expense rises by about $7.5 million per year on the new notes, since the retired 2027 Notes carried no coupon.

In exchange, Guardant gets about four additional years before the 2027 maturity wall and a conversion price of about $62.22^d, which is roughly a 35% premium to the February 6, 2025 reference price (implying a reference price of about $46.09). The initial conversion rate implies about 9.6 million shares on the $600 million of new notes, rising to a maximum of about 13.0 million shares under the maximum conversion rate after anti-dilution adjustments. Those shares would be issued under the Section 3(a)(9) exemption.

The new notes have investor protections that matter for valuation and risk. Holders cannot convert before November 15, 2030 except upon specified events. The company cannot call the notes before February 21, 2028, and can then redeem them only if the stock trades above 130% of the conversion price (about $80.89) for a specified period.

Calling a note triggers a make-whole conversion rate increase. Events of default include cross-acceleration on at least $100 million of debt. Investors should weigh the reduced refinancing risk against the modest increase in cash interest, the dilution potential from the conversion shares, and the partly offsetting effect of the stock repurchases.

02—Key points

Key Highlights

Guardant will issue $600 million of 1.25% Convertible Senior Notes due February 15, 2031 in exchange for retiring approximately $659.3 million of its 0% Convertible Senior Notes due 2027.
About $490.7 million of the 2027 Notes remain outstanding on unchanged terms, so the maturity wall is partly addressed but not eliminated.
Net principal reduction is about $59.3 million, while annual cash interest rises by roughly $7.5 million on the new 1.25% coupon.
The initial conversion price is about $62.22 per share, a 35% premium to the February 6, 2025 reference price of roughly $46.09, with a maximum of about 13.0 million conversion shares.
Guardant plans to repurchase about $80 million of common stock in total ($45 million directly and about $35 million through the exchange agent) at the February 6, 2025 last reported sale price.
The company cannot redeem the new notes before February 21, 2028, and then only if the stock exceeds 130% of the conversion price (about $80.89) on specified trading days.
The transaction is expected to close on or about February 14, 2025, subject to customary closing conditions, and the notes are issued under a Section 4(a)(2) private placement exemption.

03—Questions

Frequently Asked Questions

Does this transaction increase Guardant Health's debt?
Not on a principal basis. Guardant retires about $659.3 million of 2027 Notes and issues $600 million of 2031 Notes, a net reduction of about $59.3 million. However, the new notes carry a 1.25% coupon while the retired 2027 Notes were 0%, so annual cash interest expense rises by roughly $7.5 million on the $600 million principal.
How much dilution could shareholders face from the new notes?
At the initial conversion rate of 16.0716 shares per $1,000 principal, the $600 million of new notes convert into about 9.6 million shares. The filing states a maximum of about 13.0 million shares at the maximum conversion rate of 21.6966 per $1,000, subject to anti-dilution adjustments. Guardant can settle conversions in cash, shares, or a combination, which gives it flexibility to limit share issuance.
Why is Guardant repurchasing its own stock alongside the exchange?
The filing says the company intends to repurchase about $45 million of common stock from certain participants in the transaction, and its exchange agent is expected to buy about $35 million more, both at the February 6, 2025 last reported sale price. These repurchases are tied to the exchange and likely reflect holders of the 2027 Notes hedging or unwinding positions. The filing does not explicitly explain the purpose beyond this linkage, and the repurchases partially offset the dilution from the new notes.
When can holders convert the new notes, and when can Guardant force conversion or redeem them?
Before November 15, 2030, holders can convert only upon specified events. From November 15, 2030 until the second trading day before maturity, they can convert at any time. Guardant cannot redeem the notes before February 21, 2028. After that date, it can redeem them at par plus accrued interest only if the stock exceeds 130% of the conversion price (about $80.89) on at least 20 of 30 consecutive trading days. Calling a note also triggers a make-whole adjustment that increases the conversion rate for holders who convert after the call.
What are the main default and acceleration risks for the new notes?
Events of default include payment defaults, failure to send required notices, certain merger or asset-sale covenant breaches, other covenant defaults not cured within 60 days, cross-default on indebtedness of at least $100 million by the company or significant subsidiaries, and bankruptcy events. Bankruptcy of the parent causes automatic acceleration. For other defaults, the trustee or holders of at least 25% of principal can accelerate. For certain reporting failures, the company can elect special interest of up to 0.50% for up to 180 days as the sole remedy.

04—Continue

← View all 8-K filings